Comparative Study of Safety and Efficacy of Two Hyaluronic Acids for the Treatment of Knee Osteoarthritis Pain

NCT ID: NCT01295580

Last Updated: 2021-04-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 349 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-01-31
• Study Completion Date: 2012-02-29

Brief Summary

The purpose of this study is to determine the comparative safety and efficacy of intra-articular injection of hyaluronic acid, obtained from two different sources, in the treatment of osteoarthritic pain of the knee.

Detailed Description

This is a multicenter, randomized, double blind, parallel-controlled clinical trial using a non-inferiority comparison to evaluate the efficacy and safety of an intra-articular injection of Durolane® vs Artz® in the treatment of knee osteoarthritis. Subjects will be randomized 1:1 to receive either Durolane or Artz. All subjects will be followed up for 26 weeks from the initial treatment.The screening period is expected to be up to 2 weeks in duration before the baseline visit. Each subject will provide a written informed consent and undergo a qualifying screening. Assessment at screening will include postero-anterior view of standing weight-bearing semi-flexed radiographs of the study knee. The osteoarthritis changes of the study knee will be graded 0,1,2,3 or 4 according to the Kellgren-Lawrence radiographic scoring criteria. Radiographic assessment will be made by an assigned and well trained investigator at each study center. The study knee and contralateral knee will use the Likert WOMAC 5-point scoring for pain assessment.

Physical examination of the knees and vital signs will be performed (this examination will be repeated at end).

Conditions

Knee Osteoarthritis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

ARTZ sodium hyaluronate

The comparator product, ARTZ, is manufactured by Seikagaku Corporation, Japan. Subjects randomized to the ARTZ group were administered five weekly intra-articular injections (2.5 ml, NASHA 25 mg). ARTZ is a sterile, viscoelastic nonpyrogenic solution of purified, high molecular weight (620,000-1,170,000 daltons) sodium hyaluronate having a pH of 6.8-7.8. The sodium hyaluronate is extracted from chicken combs.

Group Type: ACTIVE_COMPARATOR

ARTZ

Intervention Type: DEVICE

Hyaluronic acid (five 2.5 mL injections)

DUROLANE hyaluronic acid

The investigational product was provided in pre-filled syringes containing stabilized non-animal hyaluronic acid (20 mg/mL). Only one injection was given for those subjects randomized to the DUROLANE group, followed by 4 sham injections. DUROLANE is free from products of animal origin and is manufactured by Q-Med AB Corporation.The sham injection procedure was same as the active injection, except that they were subcutaneous and an empty syringe was used.

Group Type: ACTIVE_COMPARATOR

DUROLANE

Intervention Type: DEVICE

Hyaluronic acid stabilized (one 3.0 mL injection + four weekly 0 mL sham injections)

Interventions

ARTZ

Hyaluronic acid (five 2.5 mL injections)

Intervention Type: DEVICE

DUROLANE

Hyaluronic acid stabilized (one 3.0 mL injection + four weekly 0 mL sham injections)

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Subject (female or male) 40-80 years of age, inclusive
• Documented diagnosis of mild to moderate osteoarthritis of the study knee that fulfil the ACR(American College of Rheumatology) criteria
• Radiographic evidence of osteoarthritis in the study knee (Kellgren Lawrence radiographic score is 2 or 3)

Exclusion Criteria

• Clinically apparent tense effusion of the study knee on examination determined by either a positive bulge sign or positive ballottement of the patella
• Kellgren-Lawrence radiographic score 0, 1 or 4 in the study knee
• Symptomatic osteoarthritis of the contralateral knee or of either hip that is not responsive to acetaminophen/paracetamol and/or requires any protocol prohibited therapies

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Smith & Nephew, Inc.

INDUSTRY

Sponsor Role: collaborator

Bioventus LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jianhao Lin, MD

Role: PRINCIPAL_INVESTIGATOR

People Hospital of Beijing University No. 11 South Ave., Xizhimen, Beijing

Locations

Beijing Frienship Hospital

Beijing, , China

Beijing General Military Hospital

Beijing, , China

Beijing University #3 Hospital

Beijing, , China

Beijing University People's Hospital

Beijing, , China

Zhejiang #2 Hospital

Hangzhou, , China

Shanghai #6 People's Hospital

Shanghai, , China

Shanghai #9 People's Hospital

Shanghai, , China

Countries

China

References

Zhang H, Zhang K, Zhang X, Zhu Z, Yan S, Sun T, Guo A, Jones J, Steen RG, Shan B, Zhang J, Lin J. Comparison of two hyaluronic acid formulations for safety and efficacy (CHASE) study in knee osteoarthritis: a multicenter, randomized, double-blind, 26-week non-inferiority trial comparing Durolane to Artz. Arthritis Res Ther. 2015 Mar 10;17(1):51. doi: 10.1186/s13075-015-0557-x.

Reference Type: RESULT

PMID: 25889322 (View on PubMed)

Other Identifiers

TG1018DLN

Identifier Type: -

Identifier Source: org_study_id